How a More Powerful CAR T-Cell Therapy Could Finally Take On Solid Tumors
CAR T-cell therapy has saved lives in blood cancers. But in solid tumors -- the most common forms of cancer -- it has barely made a dent. A new approach targeting a protein also found on senescent cells may offer a way in.
CAR T-cell therapy sounds like science fiction, but it is already real: you take T-cells from a patient's blood, genetically reprogram them to recognize a specific target, and inject them back. In leukemia and other blood cancers, the results can be spectacular. But in solid tumors -- breast, lung, colorectal cancer -- the therapy fails time and again. The reason is that tumors surround themselves with a hostile environment that exhausts and excludes T-cells before they can do any damage.
Researchers have now described a strategy that partly sidesteps that problem: they direct CAR T-cells at uPAR, a protein expressed on the surface of senescent cells -- cells that can no longer divide but also refuse to die cleanly. These so-called "zombie cells" accumulate in aging tissue and in the area surrounding tumors, where they form a protective shield that undermines the immune system. By attacking those cells, the therapy goes after the tumor and its protective layer at the same time.
Hitting Two Targets at Once
What makes this approach particularly interesting for longevity research is its dual action. uPAR has long been studied as a target for clearing senescent cells from aging tissue -- not to treat cancer, but to slow aging itself. In that context, CAR T-cell therapies are too expensive and complex for widespread use. In oncology, however, they already are in use. The new study suggests that uPAR-targeted therapy works better against solid tumors than earlier approaches, with the cells penetrating deeper into the tumor and remaining active for longer.
The results are promising in animal studies, but clinical trials in humans are still in their early stages. CAR T-cell therapy is also expensive -- treatments can easily run into the hundreds of thousands of euros -- which severely limits accessibility. That is not a technical problem but a structural economic one, entirely separate from how well the therapy actually works.
Aging and Cancer Are Deeply Intertwined
The study also illustrates a broader trend: aging and cancer are increasingly being investigated as interconnected processes. Senescent cells are not simply unwanted byproducts of aging; they play an active role in driving tumor growth. Therapies that tackle both problems at once -- senolytics, the class of agents that clears out senescent cells -- are in full development. Whether uPAR-targeted CAR T-cells will earn a place in that toolkit depends on the results that clinical trials produce in the years ahead.